10-Q: MetaVia Inc. Reports Q1 2025 Financial Results, Highlights Progress in MASH and Obesity Programs

MetaVia Inc. announces its Q1 2025 financial results, showcasing a decrease in net loss compared to the previous year and providing updates on its DA-1241 and DA-1726 clinical trials.

Summary

• MetaVia Inc. is a clinical-stage biotechnology company focused on developing treatments for cardiometabolic diseases, particularly MASH and obesity.
• The company's lead programs include DA-1241, a GPR119 agonist for MASH and Type 2 Diabetes, and DA-1726, an OXM analog agonist for obesity.
• For the three months ended March 31, 2025, MetaVia reported a net loss of $3.7 million, or $0.36 per share, compared to a net loss of $6.7 million, or $1.32 per share, for the same period in 2024.
• Research and development expenses decreased by $2.6 million to $2.3 million, primarily due to decreased activities related to the Phase 2a clinical trial for DA-1241 and increased activities related to the Phase 1 trial for DA-1726.
• General and administrative expenses decreased by $0.4 million to $1.6 million.
• As of March 31, 2025, MetaVia had $11.2 million in cash and believes this will be sufficient to fund operations into 2026.
• The company plans to continue funding operations through equity offerings, debt financing, or other sources, including potential collaborations and out-licensing.
• MetaVia is currently finalizing the Clinical Study Report on a Phase 2a clinical trial in the United States (U.S.).
• The Company expects to have an end-of-Phase 2 meeting with the FDA in the first half of 2025.
• The enrollment for the additional cohorts is expected to begin in the third quarter of 2025 with data expected in the fourth quarter of 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, the decrease in net loss and positive clinical trial data are encouraging. However, the going concern uncertainty and need for additional funding temper the positive aspects.

Positives

• The net loss decreased significantly compared to the same period last year.
• R&D expenses decreased, indicating potential efficiency improvements or strategic shifts in development programs.
• The company has cash reserves projected to last into 2026.
• Positive top-line data was announced from the Phase 1 trial of DA-1726.
• A private placement transaction closed in May 2025, providing additional funding.
• The company expects to have an end-of-Phase 2 meeting with the FDA in the first half of 2025 regarding DA-1241.

Negatives

• The company continues to experience net losses and negative cash flows from operating activities.
• There is substantial doubt about the company's ability to continue as a going concern within one year without additional funding.
• The company's disclosure controls and procedures were not effective as of the end of the period covered by this Report, as a result of the material weaknesses in our internal control over financial reporting.
• The company is in the process of remediating, but has not yet remediated, the material weaknesses, as described above, related to logical access over the accounting software and lack of review over reconciliation of accrued clinical trial liabilities.

Risks

• The company's ability to secure additional funding is uncertain.
• Raising additional funds through equity offerings may result in significant dilution for stockholders.
• Debt financing, if available, may involve restrictive covenants.
• Failure to raise additional capital may lead to slowing down or stopping clinical trials.
• Changes in U.S. trade policy could negatively impact costs and supply chains.
• The company's disclosure controls and procedures were not effective as of the end of the period covered by this Report, as a result of the material weaknesses in our internal control over financial reporting.

Future Outlook

MetaVia believes its existing cash will be sufficient to fund operations into 2026 and plans to continue funding operations through equity offerings, debt financing, or other sources, including potential collaborations and out-licensing.

Management Comments

• Currently, we are planning to add higher-dose cohorts to assess the maximum tolerated dose and fully realize DA-1726's potential, as higher doses may also show a similar profile, while potentially demonstrating increased weight reduction.

Industry Context

MetaVia is operating in the competitive biotechnology industry, focusing on cardiometabolic diseases such as MASH and obesity, which are areas of significant unmet medical need and growing market opportunity. The company's progress in clinical trials and potential collaborations could position it favorably within the industry.

Comparison to Industry Standards

• It is difficult to compare MetaVia's results directly to industry standards without knowing the specific details of their clinical trial designs and the performance of comparable companies.
• However, companies like Intercept Pharmaceuticals (now Almirall) and Madrigal Pharmaceuticals are key players in the MASH space, and their clinical trial results and market capitalization could serve as benchmarks.
• In the obesity market, companies like Novo Nordisk and Eli Lilly have set high standards with their GLP-1 receptor agonists, and MetaVia's DA-1726 will need to demonstrate competitive efficacy and safety to gain market share.

Related Party Transactions

• We entered into a license agreement with Dong-A ST Co., Ltd. (Dong-A ST) pursuant to which we received an exclusive global license (except for the territory of the Republic of Korea) for two proprietary compounds for specified indications (the 2022 License Agreement) upon meeting certain financing milestones.
• In connection with the 2022 License Agreement, we entered into a shared services agreement with Dong-A ST (the Shared Services Agreement), relating to DA-1241 and DA-1726, pursuant to which Dong-A ST may provide technical support, preclinical development, and clinical trial support services on terms and conditions acceptable to both parties.
• In May 2025, MetaVia closed on a private placement transaction pursuant to a securities purchase agreement with Dong-A ST, a related party, and Dong-A Socio Holdings Co., Ltd., the parent company of Dong-A ST (the Securities Purchase Agreements).

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional funds through equity offerings.
• Employees are subject to the risk of potential slowdowns or cessation of clinical trials if the company cannot secure additional funding.
• Customers (potential patients) may benefit from the successful development of new treatments for MASH and obesity.
• Suppliers and creditors face the risk of potential payment delays or defaults if the company's financial situation deteriorates.

Next Steps

• Finalizing the Clinical Study Report on a Phase 2a clinical trial in the United States (U.S.).
• The Company expects to have an end-of-Phase 2 meeting with the FDA in the first half of 2025.
• The enrollment for the additional cohorts is expected to begin in the third quarter of 2025 with data expected in the fourth quarter of 2025.

Key Dates

Keywords

MetaVia, financial results, clinical trials, DA-1241, DA-1726, MASH, obesity, biotechnology, GPR119 agonist, OXM analog agonist, net loss, R&D expenses, cash flow, funding, FDA, private placement, going concern, internal control